Consistent with this finding, RGFP966 treatment reduced renal ferroptosis and fibrosis in AKI-CKD mice, with a modulation in the expression of GPX4, a master regulator of ferroptosis, implicating a key role of HDAC3 in AKI-CKD transition (117). The gene discussed is HDAC3; the disease is chronic kidney disease.